POLYPHOTONIX NOCTURA 500 MEDICAL DEVICE DEVELOPMENT
Lead Participant:
POLYPHOTONIX LIMITED
Abstract
PolyPhotonix Ltd, an innovative UK SME, based in the North East of England will develop a
prototype light therapy sleep mask "Noctura 500" for the treatment of wet age related macular
degeneration (Wet AMD). The Noctura 500 concept results from earlier in-house R&D
activities in the area of Organic Light Emitting Diode (OLED) technology. Through
cooperation with clinical partners, PolyPhotonix will participate in early stage clinical trials to
show safety and proof of principle of the proposed device.
PolyPhotonix seek to provide a non-invasive, monitored but home-based treatment as an
alternative to the current intraocular injections received in a hospital environment for wet
AMD. The light therapy mask aims at prevention and halting disease progression; thus
maintaining eye health and visual acuity in an ageing population.
prototype light therapy sleep mask "Noctura 500" for the treatment of wet age related macular
degeneration (Wet AMD). The Noctura 500 concept results from earlier in-house R&D
activities in the area of Organic Light Emitting Diode (OLED) technology. Through
cooperation with clinical partners, PolyPhotonix will participate in early stage clinical trials to
show safety and proof of principle of the proposed device.
PolyPhotonix seek to provide a non-invasive, monitored but home-based treatment as an
alternative to the current intraocular injections received in a hospital environment for wet
AMD. The light therapy mask aims at prevention and halting disease progression; thus
maintaining eye health and visual acuity in an ageing population.
Lead Participant | Project Cost | Grant Offer |
|---|---|---|
| POLYPHOTONIX LIMITED | £555,526 | £ 249,986 |
People |
ORCID iD |